Iovance Reports Inducement Grants Under NASDAQ Listing Rule
Iovance Biotherapeutics has granted inducement stock options for 62,790 shares to nine new non-executive hires. The options are priced...
No videos found.
Xoma Royalty, Lava Therapeutics Amend Purchase Agreement
XOMA Royalty Corporation has amended its definitive agreement to acquire LAVA Therapeutics, cutting the initial cash consideration to $1.04...
Newgen Enters Art Tokenization Market with $2M Deal
NewgenIVF Group has signed an agreement to act as the worldwide agent for tokenizing the World Chinese Museum’s private...
CorMedix Surging, Raises 2025 Net Revenue Guidance
CorMedix posted preliminary third-quarter 2025 results showing more than $100 million in net revenue, at least $85 million from...
OGRD Alliance’s Surging, Successful Growth in Asia, MENA
OGRD Alliance is expanding its PLPC-DB phospholipoproteomic module and its Oncovix documentation program from Dubai into Asia and the...
Surging Ryoncil® Revenues: A Remarkable 69% Q2 Increase
Mesoblast reported a sharp step-up in commercial momentum for Ryoncil, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid‑refractory...
Rani Soars With Oversubscribed $60.3M Private Placement
Rani Therapeutics has raised approximately $60.3 million in an oversubscribed private placement, selling Class A common stock and pre-funded...
Rani Therapeutics Soars with $1B Chugai Drug Collaboration
Rani Therapeutics has signed a collaboration and license agreement with Chugai Pharmaceutical to develop and commercialize an oral version...
XORTX Acquires Renal Anti-Fibrotic Program from Vectus
XORTX Therapeutics has signed a binding term sheet to acquire Vectus Biosystems’ renal anti-fibrotic program, anchored by the novel...
i-mab to Rebrand as Novabridge, Eyes Hong Kong IPO
I-Mab is pivoting to a new operating model and identity, unveiling plans to rebrand as NovaBridge Biosciences, pursue a...